0001209191-22-018667.txt : 20220314 0001209191-22-018667.hdr.sgml : 20220314 20220314195936 ACCESSION NUMBER: 0001209191-22-018667 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220311 FILED AS OF DATE: 20220314 DATE AS OF CHANGE: 20220314 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Detheux Michel CENTRAL INDEX KEY: 0001816196 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39401 FILM NUMBER: 22738432 MAIL ADDRESS: STREET 1: C/O ITEOS THERAPEUTICS, INC. STREET 2: 139 MAIN STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: iTeos Therapeutics, Inc. CENTRAL INDEX KEY: 0001808865 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 321 ARSENAL STREET STREET 2: BLDG 312, FLOOR 3, SUITE 301 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 857-204-4583 MAIL ADDRESS: STREET 1: 321 ARSENAL STREET STREET 2: BLDG 312, FLOOR 3, SUITE 301 CITY: WATERTOWN STATE: MA ZIP: 02472 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-03-11 0 0001808865 iTeos Therapeutics, Inc. ITOS 0001816196 Detheux Michel 321 ARSENAL STREET WATERTOWN MA 02472 0 1 0 0 Chief Executive Officer Common Stock 2022-03-11 4 A 0 10000 0.00 A 44700 D Stock Option (Right to Buy) 36.21 2022-03-11 4 A 0 352500 0.00 A 2032-03-11 Common Stock 352500 352500 D The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying such RSUs will vest on the first anniversary of the grant date, and the remaining shares subject to the RSUs will vest on a quarterly basis thereafter in equal installments over the following twelve (12) quarters, subject to the Reporting Person's continued service to the Issuer. This stock option shall vest over 4 years, with 25% vesting on March 11, 2023 and thereafter in equal monthly installments over the next 36 months, subject to the Reporting Person's continued service to the Issuer. /s/ Adi Osovsky, as Attorney-in-Fact 2022-03-14